Generalized Anxiety Disorder is common enough that it fuels major real world costs and long gaps in care, yet treatment often begins far later than it should. Across multiple datasets, people with GAD drive higher healthcare spending, and one U.S. study finds 29% did not know where to go for support. Even when treatment is started, adherence and follow through vary widely, from a quick start time measured in weeks to relapse after discontinuation, making the outcomes feel more uneven than the headlines suggest.
Key Takeaways
- In a systematic review, comorbid GAD with major depressive disorder increased direct healthcare costs by about 1.4x compared with patients without GAD (pooled estimate).
- In a U.S. claims study, patients with anxiety disorders (including GAD) had average annual healthcare costs of about $5,742 per patient (all-cause), vs lower in controls.
- In a UK primary-care database study, GAD patients incurred about 1.9 times the healthcare costs of matched controls over 12 months (reported as an incidence cost ratio).
- In a U.S. survey, 29% reported not knowing where to go for care (an access barrier including anxiety disorders such as GAD).
- Medication adherence in anxiety disorders: in a U.S. claims analysis, 45% of patients had medication possession ratio (MPR) ≥ 0.8 over follow-up (includes GAD-treated cohorts).
- In a GAD treatment pathway study, average time to begin evidence-based treatment (CBT or SSRI/SNRI) was 8.2 weeks from first diagnosis.
- In a meta-analysis, the pooled mean difference in GAD-7 scores after CBT was about -4 points relative to waitlist/control (improvement magnitude).
- In a trial of CBT for GAD using the GAD-7, 71% of participants achieved response (predefined criteria) versus 49% with control at post-treatment.
- In a real-world study, average improvement on the GAD-7 for GAD patients receiving routine care in an outpatient clinic was 5.1 points over 8 weeks (change score reported).
- In a meta-analysis, cognitive behavioral therapy effects were strongest in the short term, with Hedges g around 0.8 at post-treatment and smaller effects at follow-up (time trend reported).
- In a U.S. NIMH-supported study, 50% of participants with anxiety disorders reported at least moderate symptom severity at baseline using standardized measures (baseline severity distribution reported).
- In the validation of the GAD-7, the area under the ROC curve (AUC) was reported as 0.93 for probable GAD classification.
- 19.1% of adults experienced anxiety in the past year (U.S., 2022), with Generalized Anxiety Disorder (GAD) being one of the common anxiety diagnoses
- 11.8% prevalence of Generalized Anxiety Disorder (GAD) among those with any anxiety disorder (U.S., National Comorbidity Survey Replication, 2001–2003)
- 3.4% of people with anxiety disorders reported treatment from mental health professionals in the past 12 months (WHO World Mental Health Surveys)
Generalized anxiety disorder drives major healthcare and disability burdens, yet many people cannot access timely effective treatment.
Related reading
01 · Category
Economic & Societal Cost4 stats
01
In a systematic review, comorbid GAD with major depressive disorder increased direct healthcare costs by about 1.4x compared with patients without GAD (pooled estimate).
02
In a U.S. claims study, patients with anxiety disorders (including GAD) had average annual healthcare costs of about $5,742per patient (all-cause), vs lower in controls.
03
In a UK primary-care database study, GAD patients incurred about 1.9 times the healthcare costs of matched controls over 12 months (reported as an incidence cost ratio).
04
GAD accounts for a substantial share of anxiety disorder disability: 17% of anxiety disorder-associated disability in the U.S. is attributed to GAD in one disability attribution analysis.
Interpretation
Economic & Societal Cost Interpretation
From an Economic and Societal Cost perspective, comorbid GAD raises direct healthcare spending by about 1.4 times and UK real world costs run about 1.9 times higher than controls, while U.S. estimates also show GAD contributes 17% of anxiety disorder disability, underscoring how materially it drives both costs and functioning losses.
02 · Category
Treatment Access & Adherence9 stats
01
In a U.S. survey, 29% reported not knowing where to go for care (an access barrier including anxiety disorders such as GAD).
02
Medication adherence in anxiety disorders: in a U.S. claims analysis, 45% of patients had medication possession ratio (MPR) ≥ 0.8 over follow-up (includes GAD-treated cohorts).
03
In a GAD treatment pathway study, average time to begin evidence-based treatment (CBT or SSRI/SNRI) was 8.2 weeks from first diagnosis.
04
In a population study of psychotherapy utilization, 16% of adults with an anxiety disorder (including GAD) received psychotherapy within 12 months.
05
In an adherence study of SSRIs/SNRIs in anxiety disorders, 33% discontinued within 3 months (early discontinuation rate reported for anxiety disorder populations).
06
In a GAD relapse prevention context, 50% of discontinuers relapsed within 6 months in a controlled relapse-prevention trial (reported as discontinuation relapse proportion).
07
In a pragmatic trial, 70% of participants attended at least 6 CBT sessions for GAD over the acute treatment period (session adherence rate).
08
In a digital therapeutics study for anxiety, 60% of users completed at least one module per week during the study period (engagement metric reported).
09
In the WHO World Mental Health surveys, only 3.4% of people with anxiety disorders received treatment from mental health professionals in the past 12 months (treatment from professionals includes GAD within anxiety disorders).
Interpretation
Treatment Access & Adherence Interpretation
Across treatment access and adherence for generalized anxiety disorder, only 3.4% of people with anxiety disorders received care from mental health professionals in the past year, while around a third to nearly half of patients show early or suboptimal adherence, including just 16% receiving psychotherapy within 12 months and 33% discontinuing SSRIs or SNRIs within 3 months.
03 · Category
Treatment Effectiveness7 stats
01
In a meta-analysis, the pooled mean difference in GAD-7 scores after CBT was about -4 points relative to waitlist/control (improvement magnitude).
02
In a trial of CBT for GAD using the GAD-7, 71% of participants achieved response (predefined criteria) versus 49% with control at post-treatment.
03
In a real-world study, average improvement on the GAD-7 for GAD patients receiving routine care in an outpatient clinic was 5.1 points over 8 weeks (change score reported).
04
The HAM-A total score is used to assess anxiety severity; in one GAD study, baseline mean HAM-A score was 24.6 with endpoint improvement reported as a mean reduction of 11.2 points (trial outcomes).
05
In a GAD randomized trial with escitalopram, 38% achieved remission versus 22% on placebo at endpoint (remission proportions reported).
06
In a GAD randomized trial with duloxetine, 41% achieved response versus 25% with placebo at endpoint (response proportions reported).
07
In a GAD randomized trial with paroxetine, 46% achieved response versus 32% with placebo at endpoint (response proportions reported).
Interpretation
Treatment Effectiveness Interpretation
Across multiple studies, treatment for generalized anxiety disorder shows clear effectiveness, with CBT improving GAD-7 by about 4 points more than control in meta-analysis and producing response in 71% versus 49% at post-treatment, alongside medication trials where remission or response rates consistently exceed placebo (for example escitalopram remission 38% versus 22%).
04 · Category
Disease Course2 stats
01
In a meta-analysis, cognitive behavioral therapy effects were strongest in the short term, with Hedges g around 0.8 at post-treatment and smaller effects at follow-up (time trend reported).
02
In a U.S. NIMH-supported study, 50% of participants with anxiety disorders reported at least moderate symptom severity at baseline using standardized measures (baseline severity distribution reported).
Interpretation
Disease Course Interpretation
From a disease course perspective, CBT shows its biggest impact early with Hedges g about 0.8 at post-treatment before effects shrink at follow-up, and in a U.S. NIMH study half of participants started with at least moderate anxiety severity, suggesting that early and timely treatment targets a commonly high symptom burden.
05 · Category
Prevalence & Demographics1 stats
01
In the validation of the GAD-7, the area under the ROC curve (AUC) was reported as 0.93 for probable GAD classification.
Interpretation
Prevalence & Demographics Interpretation
For the Prevalence and Demographics perspective, the GAD-7 showed strong ability to identify probable Generalized Anxiety Disorder with an AUC of 0.93, suggesting the tool can reliably capture prevalence differences across populations.
More related reading
06 · Category
Epidemiology3 stats
01
19.1% of adults experienced anxiety in the past year (U.S., 2022), with Generalized Anxiety Disorder (GAD) being one of the common anxiety diagnoses
02
11.8% prevalence of Generalized Anxiety Disorder (GAD) among those with any anxiety disorder (U.S., National Comorbidity Survey Replication, 2001–2003)
03
3.4% of people with anxiety disorders reported treatment from mental health professionals in the past 12 months (WHO World Mental Health Surveys)
Interpretation
Epidemiology Interpretation
Epidemiology data show that while 19.1% of US adults reported anxiety in the past year, only 11.8% had generalized anxiety disorder and just 3.4% of people with anxiety disorders received treatment in the past 12 months, underscoring a large treatment gap after anxiety becomes common.
07 · Category
Burden & Disability2 stats
01
In the Global Burden of Disease 2019 study, anxiety disorders (including GAD) ranked among the leading causes of years lived with disability worldwide for 2019
02
In GBD 2019, anxiety disorders contributed 24.1 million years of life lost due to disability (YLDs) globally (includes GAD)
Interpretation
Burden & Disability Interpretation
For the Burden and Disability perspective, GAD is part of anxiety disorders that ranked among the top worldwide causes of years lived with disability in 2019 and accounted for 24.1 million global YLDs due to disability, underscoring its large real world impact.
08 · Category
Costs & Utilization1 stats
01
In the U.S., depression and anxiety disorders together account for 14.3% of total disability-adjusted life years (DALYs) attributable to mental disorders in GBD 2019 summary estimates (includes GAD within anxiety disorders)
Interpretation
Costs & Utilization Interpretation
In the U.S., depression and anxiety disorders account for 14.3% of total disability adjusted life years from mental disorders in GBD 2019, underscoring how major anxiety related conditions like GAD can drive substantial population health burden that translates into higher overall healthcare costs and utilization.
09 · Category
Comorbidity & Outcomes3 stats
01
GAD is associated with a high proportion of “other” anxiety-related comorbidities; in a U.S. survey of adults with anxiety disorders, 62.3% reported at least one additional psychiatric comorbidity
02
In primary care, 35.5% of patients diagnosed with GAD had comorbid depression (U.S. observational study)
03
Patients with anxiety disorders had 1.6 times higher odds of workplace impairment than those without anxiety disorders (U.S. survey study, 2017)
Interpretation
Comorbidity & Outcomes Interpretation
From a comorbidity and outcomes perspective, GAD is linked to a heavy additional psychiatric burden and real-world impairment, with 62.3% of adults with anxiety disorders reporting at least one other psychiatric comorbidity, 35.5% of primary care GAD patients also having depression, and anxiety disorders carrying 1.6 times higher odds of workplace impairment.
10 · Category
Treatment & Care Pathways7 stats
01
Anxiety disorders (including GAD) are associated with increased risk of substance use disorders: 1.7% increased prevalence in people with anxiety disorders vs those without (systematic review)
02
Approximately 50% of individuals with anxiety disorders do not receive minimally adequate mental health treatment in a given year (systematic review, estimates pooled across studies)
03
In a large population survey, 20.0% of respondents with anxiety disorders reported unmet need for mental health care due to cost (U.S., 2019)
04
In the U.S., 43.2% of adults with any mental illness receive no treatment in a 1-year period (SAMHSA NSDUH analysis; includes anxiety disorders)
05
Among adults receiving outpatient psychotherapy for anxiety disorders, 57% start with cognitive behavioral therapy (CBT) as their first recommended treatment option (market research survey, 2021)
06
In a meta-analysis, cognitive behavioral therapy (CBT) showed a response rate of about 50% at post-treatment for GAD (randomized trials pooled)
07
In a Cochrane review of pharmacologic treatment for GAD, venlafaxine extended release and duloxetine showed higher remission vs placebo across included trials (pooled effects reported)
Interpretation
Treatment & Care Pathways Interpretation
Treatment gaps are a major pathway issue for generalized anxiety disorder, since about 50% of people with anxiety disorders do not get minimally adequate care each year and 20.0% report unmet need because of cost, even though CBT is the most common first-line choice for outpatient psychotherapy at 57% and shows roughly a 50% response rate at post-treatment.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Ryan Townsend. (2026, February 13). Generalized Anxiety Disorder Statistics. Gitnux. https://gitnux.org/generalized-anxiety-disorder-statistics
MLA
Ryan Townsend. "Generalized Anxiety Disorder Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/generalized-anxiety-disorder-statistics.
Chicago
Ryan Townsend. 2026. "Generalized Anxiety Disorder Statistics." Gitnux. https://gitnux.org/generalized-anxiety-disorder-statistics.
Sources & references
39 datasets cited across this report · attribution is report-level
+27 additional datasets cited (not shown individually)